Fidelity Investments’s Avalyn Pharma AVLN Stock Holding History

Fidelity Investments’s Portfolio AVLN Stock Details AVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$192M	Buy	+5,835,259	New	+$168M	0.01%	942

Other funds holding AVLN

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Fidelity Investments's AVLN Position: Q2 2026 in Review

Fidelity Investments opened a new position in Avalyn Pharma (AVLN) in Q2 2026: 5,835,259 shares worth $192M. The stake represents 0.01% of the portfolio and ranks #942 among its holdings.

92 funds tracked by Wall St. Rank hold AVLN as of Q2 2026.

Fidelity Investments held 5,835,259 shares of Avalyn Pharma worth $192M as of Q2 2026.
Avalyn Pharma was a new Fidelity Investments position in Q2 2026.
Avalyn Pharma made up 0.01% of Fidelity Investments's portfolio in Q2 2026, its #942 holding.
92 funds tracked by Wall St. Rank held Avalyn Pharma as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.